vutrisiran

Documented cardiac disease due to ATTR-CM: Evidence of cardiac involvement by echocardiography with end diastolic interventricular septal wall thickness of greater than 12 mm in males, and greater than 11 mm in females Presence of amyloid deposits in biopsy tissue (fat aspirate, salivary gland, median nerve connection tissue sheath, or cardiac); OR transthyretin (TTR) precursor protein identification by immunohistochemistry, scintigraphy, or mass spectrometry Patients who have all of the following characteristics: Are in New York Heart Association (NYHA) class I to III Have a history of heart failure, defined as at least one prior hospitalization for heart failure or clinical evidence of heart failure that required treatment with a diuretic Have not received a heart or liver transplant Do not have an implanted cardiac mechanical assist device (CMAD) Are not receiving other disease-modifying treatments for transthyretin amyloidosis (ATTR) Discontinuation criteria: Treatment should be discontinued if a patient receiving vutrisiran: Receives a heart or liver transplant Receives an implanted CMAD

​Amvuttra (vutrisiran) is indicated for the treatment of wild-type or hereditary transthyretin-amyloidosis in adult patients with cardiomyopathy.